In the post genome era it will soon be possible to associate a speci®c tumor type with a speci®c gene expression pro®le and to de®ne each molecular lesion characteristic of any given cancer. It is intuitive that a successful therapeutic strategy for cancer should aim at blocking the aberrant biochemical activity triggered by the oncogene or the lack of tumor suppressor gene activity that ultimately leads to full-blown neoplastic transformation. However, an attractive alternative approach entails the blockade of the transcriptional consequences of such oncogenic activities irrespective of their original biochemical nature, thus antagonizing the key transcriptional events underlying cancer pathogenesis in any speci®c neoplastic cellular population. This approach is now rendered possible by major advances along several lines of investigation: (i) the possibility of analysing gene expression through high throughput methods; (ii) a more detailed knowledge of the regulatory regions and of the transcription factors that control gene expression also facilitated in the future by a comprehensive whole genome comparative analysis of these regulatory sequences; (iii) the ability of modulating gene expression at the single gene level through various approaches both pharmacological and biochemical; (iv) the opportunity of directly antagonizing the aberrant activities of oncogenic transcription factors through a detailed knowledge of their abnormal transcriptional function; (v) the possibility of validating, in vivo, in animal models the relevance for neoplastic transformation of speci®c transcriptional events as well as of testing the ecacy of`transcription therapy' in faithful animal models of human cancer. Here, we will review the facts, the existing applications and the hypothesis underlying such therapeutic modality for cancer therapy. Oncogene (2001) 20, 3116 ± 3127.
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Introduction
The last few years have been crucial for the elucidation of the molecular mechanisms underlying the pathogenesis of human cancer and this process will be further accelerated by the detailed characterization of the human genome as well as of the genome of organisms of use in cancer research such as the mouse. Research on hemopoietic neoplasms has led the way in this respect. Speci®c chromosomal rearrangements have been linked to distinct subtypes of leukemia or associated with particular stages of disease progression or prognostic outcomes. More than 80% of myeloid leukemias have been attributed to, or associated with, one or more speci®c molecular lesions. These structural rearrangements frequently involve genes encoding transcription factors whose altered functions can interfere with regulatory cascades that have been demonstrated to be critical for controlling the growth, dierentiation and survival of normal blood cell precursors (Look, 1997) .
Aberrant activity of oncogenic and tumor suppressive transcription factors has also been extensively associated with solid tumor pathogenesis as, for instance, in the case of renal cancer and soft tissue sarcomas [e.g.: WT1 tumor suppressor (Lee et al., 1999) and the fusion genes found in sarcomas with the TLS/FUS and EWS series of fusion genes as the largest group (reviewed in Aman, 1999) ].
Finally aberrant transcriptional activity has been associated with numerous inherited syndromes. In this respect, some of the transcription factors there implicated such as the Gli family of Zinc ®nger proteins lay at the functional boundary between control of developmental processes and cancer pathogenesis (reviewed in Ruiz i Altaba, 1999). As an example, Gli proteins can regulate the Hedgehog signaling in normal development, lead to inherited diseases when mutated (e.g. Polydactyly type A and Pallister-Hall Syndromes) and possibly participate in CNS cancer pathogenesis.
Thus, numerous transcription factors have been directly involved in disease pathogenesis and many more will be in the immediate future. While the lack of drugable' transcriptional targets was limiting only ten years ago, this can no longer be regarded as the limiting step in developing suitable transcriptional therapeutic strategy.
It could nevertheless be argued that the majority of neoplastic and non-neoplastic disorders are not directly due to aberrant transcription. However, it is intuitive that any signaling event will eventually need to be transduced in the nucleus at the transcription level. For instance, activation of the Hedgehog signaling pathway is executed transcriptionally, at least in part, by the Gli factors. Thus, the blockade of the transcriptional consequences of an oncogenic event may be relevant for developing eective therapeutic strategies irrespective of the biochemical nature of the tumorigenic signal (Figure 1) . A key example of the critical relevance of transcriptional events for cancer pathogenesis in the presence of oncogenic events originated at a dierent level such as cytosolic aberrant kinase activity, is oered by the TEL-JAK2 fusion oncoprotein, a constitutively active tyrosine kinase, associated with human leukemia. It has been recently demonstrated that the oncogenic potential of TEL-JAK2 totally depends on the proper function of transcription factors of the Stat family as in the absence of Stat5a and b functions the leukemogenic activity of the fusion protein is markedly impaired (Schwaller et al., 2000) .
Assuming that, in the future, critical transcriptional events will be identi®ed and validated for any neoplastic disease, how do we utilize this information for developing eective transcription therapy strategies? Two levels of therapeutic intervention can be entertained, each discussed in detail in this review ( In this latter approach, it might also be possible to act only on a few, selected and relevant subset of target genes, instead of antagonizing the function of a speci®c transcription factor globally. This intervention should render the therapeutic eects more selective and possibly less toxic.
Developing`transcription therapy' for cancer
In a few years, the advent of CGH and SNIP microarray technology, powerful tools for karyological analysis such as SKY, and the complete characterization of the human and mouse genomes will render possible the identi®cation of virtually all the genetic lesions that associate with a speci®c form of cancer. Thus, the identi®cation of cancer associated genetic events will no longer be a limiting step in cancer research. As an immediate consequence, many more transcription factors will be directly implicated in cancer pathogenesis. It will also be possible to compile comprehensive expression pro®les for each cancer subtype thus identifying the subset of genes that are up-or down-regulated as a consequence of oncogenic activities of various biochemical natures.
What will be limiting, instead, is our ability to test in vivo, in a relevant physiological context, the relative importance of such transcriptional events for cancer pathogenesis. This step, which is of critical importance to identify molecular events that are worth targeting for therapy will be however tremendously facilitated by the possibility to introduce in the mouse genome virtually any desired mutation. The validation in animal models of drugable targets can occur at multiple levels such as ( Figure 2 ): (i) the analysis of the oncogenic potential of an aberrant transcription factor in cancer pathogenesis. For instance, others and we have been able to demonstrate in vivo in transgenic Figure 1 Targets for transcription therapy. In normal cells (a), proliferation, dierentiation and survival stimuli are transduced at the transcription level leading to the proper expression of target genes required for the regulation of these biological functions. In the neoplastic cell (b), transcription factors can be mutated resulting in inappropriate expression of target genes. Alternately, an aberrant stimulus can result in the aberrant transcriptional activity of otherwise normal transcription factors and, in turn, in an inappropriate regulation of gene expression. In either cases, these tumorigenic activities can be antagonized at two main levels: (1) by directly modulating the global activity of the aberrant transcription factor (e.g. through the use of HDACIs in the case of transcriptional repressors that utilize such enzymatic activity); and (2) by acting downstream the transcription factor through the modulation of a selected number of critically important target genes mice that the PML-RARa fusion protein of acute promyelocytic leukemia (APL) is critical for leukemogenesis since mutants harboring such a fusion gene do develop leukemias with promyelocytic feature. Thus, the aberrant transcriptional activity of PML-RARa is worth targeting for eective therapy (see following paragraphs); (ii) the analysis of the transcriptional consequences of a speci®c aberrant transcription factor by comparison of expression pro®le in the human cancerous cells and in the transgenic mouse harboring the human oncogenic transcription factor. As an example, PML-RARa transgenic mice will also be extremely useful in order to perform a comparative analysis of pattern of gene expression between leukemic cells from transgenic mice and human APL blasts, which will facilitate the identi®cation of relevant PML-RARa target genes; (iii) the validation of the importance of a speci®c transcriptional event for any oncogenic activity. For instance, once target genes of the PML-RARa aberrant transcriptional activity have been identi®ed it would be possible to test their relevance in the following way: by intercrossing PML-RARa transgenic mice with mice lacking the function of the target gene. If that gene is essential the leukemogenic activity of PML-RARa may be accelerated and/or decelerated. By contrast, if the target gene is irrelevant tumor onset and/or incidence will be unperturbed. A compelling example of the ecacy of this strategy has been recently obtained studying the leukemogenic potential of TEL-JAK2 in various genetic backgrounds in the mouse. Gilliland and colleagues could demonstrate that the oncogenic potential of this molecule totally depends on the proper function of the Stat5a and b transcription factors since leukemogenesis by TEL-JAK2 is completely blocked in Stat5a and b 7/7 cells (Schwaller et al., 2000) . Based on these ®ndings, it is logical to hypothesize that a therapeutic approach aimed at speci®cally blocking Stat5a and b function should be extremely bene®cial in these leukemias; (iv) ®nally, it will be possible to test the ecacy of transcriptional therapeutic strategy in preclinical studies in faithful mouse models of cancer (see following paragraphs). This will also tremendously facilitate testing the ecacy of these novel drugs in combination with already known eective compounds, which otherwise will be an expensive and time consuming exercise if performed in clinical trials on human patients.
APL: a paradigm for aberrant transcription in cancer pathogenesis
APL, M3 subtype of acute myeloid leukemia (AML), accounts for more than 10% of all AMLs and is characterized by three distinctive and unique features (reviewed in He et al., 1999; Melnick and Licht, 1999) : (i) the accumulation in the bone marrow of tumor cells with promyelocytic features; (ii) the invariable association with speci®c reciprocal chromosomal translocations always involving the Retinoic Acid Receptor a (RARa) gene on chromosome 17. The involvement of RARa, still to date one of the most well studied transcription factor, in the pathogenesis of APL made this leukemia a straightforward example of aberrant transcription in cancer; and (iii) the exquisite sensitivity Figure 2 A strategy for the development and optimization of transcription therapy for cancer. The various stages of the process are indicated: from the identi®cation of relevant target genes or aberrant transcription factors in human cancer pathogenesis, to the in vivo validation of these`druggable targets' in animal models. Animal models can be utilized for multiple purposes as described in the text: from the evaluation of the oncogenic potential of aberrant transcriptional events, to the analysis of the ecacy of transcriptionally active compounds for Transcription Therapy (TT) in faithful animal models of human cancer of APL blasts to the dierentiating action of Retinoic Acid (RA). From this point of view APL has become the paradigm for therapeutic approaches utilizing dierentiating agents. This therapeutic approach is conceptually new in that it does not involve chemical or physical agents to eradicate the tumor by`killing' the neoplastic cells, but rather reprograms these cells to dierentiate normally. However, although eective, treatment with RA alone in APL patients induces disease remission transiently and relapse is inevitable if remission is not consolidated with chemotherapy.
In the majority of APL patients, the translocation involves chromosome 15 and 17. The breakpoints on chromosome 15 cluster within a locus originally called myl and now named PML (for ProMyelocytic Leukemia gene). In a few cases, the translocation involves chromosome 11 instead of chromosome 15, and a gene named Promyelocytic Leukemia Zinc Finger (PLZF). In rare cases the translocation involves chromosomes 5, 11 and 17 and the Nucleophosmin (NPM), the NuMA and the Stat5b genes respectively (He et al., 1999; Melnick and Licht, 1999 and references therein; Arnould et al., 1999) . The X-RARa and RARa-X fusion genes (whereby for X we indicate the various RARa partner genes) generated by the reciprocal translocation in APL encode for structurally dierent X-RARa and RARa-X products, co-expressed in the leukemic blast, which dier in their X portions, but are identical in their RARa portion, and that can therefore be considered as RARa mutants.
APL harboring the various translocations are morphologically indistinguishable, however, APL associated with chromosomal translocations between the RARa and the PLZF genes (PLZF-RARa) shows a distinctly worse prognosis with poor response to chemotherapy and little or no response to treatment with RA, thus de®ning a new APL syndrome (Licht et al., 1995) .
RARs are members of the superfamily of nuclear hormone receptors that act as RA inducible transcriptional activators, in their heterodimeric form with Retinoid-X-Receptors (RXRs), a second class of nuclear retinoid receptors (Chambon, 1996 and references therein). X-RARa proteins are always able to bind to retinoic acid response elements (RARE), and can form multimeric complexes with RXRs (He et al., 1999; Melnick and Licht, 1999 and references therein). Therefore, X-RARa proteins are thought to interfere with the normal RAR/RXR-RA pathway in a dominant negative manner through their ability to complex with RXR, and/or through their altered DNA binding and transcriptional activities. X-RARa can also heterodimerize with X in view of the fact that X normally homodimerize, and that the X homodimerization interface is retained in the moiety of X which fuses to RARa. Thus X-RARa can act, in principle, as double dominant negative oncogenic products, interfering with both X and RAR/RXR-RA pathways (He et al., 1999; Melnick and Licht, 1999 and references therein). However, PML-RARa and PLZF-RARa proteins retain intact RARa DNA and ligand binding domains, and have an anity for the ligand comparable to that of the wild-type RARa (He et al., 1999; Melnick and Licht, 1999 and references therein) . For these reasons, the molecular mechanisms by which both X-RARa molecules would be leukemogenic at physiological doses of RA, and would behave dierently at pharmacological doses of RA, remained until recently unexplained. As a more fundamental corollary, it was also unclear if APL was caused by the aberrant RA-dependent transactivation of gene expression by X-RARa proteins since, in this case, APL should always be exacerbated by RA, while, on the contrary and paradoxically, RA is extremely eective in APL cases harboring PML-RARa. The elucidation of the transcriptional basis of the dierential responses to RA in APL was therefore crucial for the understanding of APL pathogenesis itself, and would go beyond simply clarifying the mechanisms underlying RA resistance in APL.
Transcriptional silencing in APL pathogenesis: a rationale for transcription therapy for APL with HDACIs and engineered peptides Others and we have recently de®ned the aberrant transcriptional activity of the X-RARa fusion proteins, which, in a uni®ed model, provide a transcriptional rationale for both the molecular pathogenesis of APL and the dierential response to RA in APL (He et al., 1998a; Lin et al., 1998; Grignani et al., 1998) . In the absence of RA, RAR/RXR heterodimers can repress transcription through histone deacetylation by recruiting nuclear receptor co-repressors (N-CoR or SMRT), Sin3A or Sin3B, which in turn form complexes with histone deacetylases (HDAC1 or 2), thereby resulting in nucleosome assembly and transcriptional repression (Grunstein, 1997 and references therein) . The presence of RA, at physiological concentrations, induces an allosteric change in the receptor leading to the dissociation of the co-repressors complex, and the recruitment of transcriptional co-activators to the RAR/RXR complex, thus resulting in the activation of gene expression which, in turn, can induce terminal dierentiation and growth arrest of cells of various histological origins including normal myeloid hemopoietic cells (Smith et al., 1992; Gudas et al., 1994 and references therein) (Figure 3 ). It was found that at this concentration of the ligand X-RARa proteins act as potent transcriptional repressors in view of an increased and aberrant anity for nuclear co-repressors and HDACs (He et al., 1998a; Lin et al., 1998; Grignani et al., 1998) (Figure 3 ). At pharmacological dose of RA, while PML-RARa can be freed from corepressors interactions thus directly mediating transactivation of RARa target genes, PLZF-RARa, via the PLZF moiety, renders the leukemic cells RA unresponsive through co-repressor/HDAC interactions insensitive to RA (He et al., 1998a; Lin et al., 1998; Grignani et al., 1998) . Histone deacetylase inhibitors (HDACIs) such as Trichostatin A (TSA), sodium phenylbutyrate (PB), and suberanilohydroxamic acid (SAHA) (Richon et al., 1996 , in combination with RA, could overcome the transcriptional repressive activity of PML-RARa and PLZF-RARa (He et al., 1998a; Lin et al., 1998; Grignani et al., 1998 and our unpublished observations). HDACIs could also overcome the unresponsiveness of PLZF-RARa leukemic cells to RA (He et al., 1998a) .
These ®ndings unraveled a crucial role for transcriptional silencing in APL pathogenesis and resistance to RA in APL and also suggested that HDACIs alone or in combination with RA might be utilized for the treatment of this leukemia to speci®cally antagonize the aberrant transcriptional activity of the various XRARa oncoproteins.
These data also provided a direct explanation for the repressive ability of PLZF-RARa, however little was known about the molecular mechanisms underlying the ability of the other X-RARa fusion proteins to repress transcription. It has been recently reported that the repressive ability of the mutant receptors maybe strictly dependent on their oligodimerization capabilities (Lin and Evans., 2000; Minucci et al., 2000; Salomoni and Pandol®, 2000) . X-RARa homodimer could compete with RARa for binding of RXR. The fusion of any dimerization motif to RARa appears to be sucient for recruitment of co-repressor and RA unresponsiveness. Therefore, oligomerization is important for the XRARa oncogenes to interfere with the normal RARa function and repress transcription of RA-responsive genes. A straightforward implication of these latter ®ndings is that the delivery of engineered peptides that contain the dimerization domain of the various XRARa proteins could interfere with the formation of X-RARa homodimers/holigomers, antagonizing their aberrant transcriptional repressive activity and be an eective therapy for APL.
Thus, the understanding of the aberrant transcriptional mechanisms in APL pathogenesis has allowed the proposal of a novel therapeutic paradigm, which we termed transcription therapy for cancer with transcriptionally active compounds, whereby it would be possible to induce eective therapeutic responses through the speci®c blockade of aberrant transcriptional activities and/or of their downstream consequences. While APL could be regarded as a paradigm of neoplasias directly associated/caused by aberrant transcription factors, transcriptionally active compounds could be utilized, in principle, in any form of cancer and non-neoplastic disease, even if transcriptional deregulation is only the consequence and not the triggering event of the human condition (Figure 1) .
Indeed, we have already successfully utilized Sodium Phenylbutyrate (SPB), a HDACI, in combination with RA for the treatment of one case of APL refractory to multiple chemotherapeutic regiments as well as to RA . Treatment with SPB+RA induced long lasting clinical and molecular remission in this APL case . This preliminary attempt of transcription therapy has been rendered possible by the fact that SPB was previously approved for clinical use as a single agent in the treatment of b- Figure 3 Transcriptional repression in APL leukemogenesis. RA, at physiological concentrations, induces the release of the RARa/ RXRa/co-repressor/HDAC complex, the formation of a RARa/RXRa/co-activator complex and, in turn, the activation of transcription of genes possibly required for cellular dierentiation and growth inhibition (top). At this concentration of RA, the XRARa proteins are potent transcriptional repressors in view of an increased and aberrant anity for nuclear co-repressors and HDACs (bottom) thalassemia, due to its ability to induce the expression of the g-globin gene (Dover et al., 1992) . Other novel and more potent HDACIs are presently been tested in Phase I and II clinical trials (see following paragraphs).
Testing transcription therapy in faithful animal models of APL If one would wish to test the ecacy of a novel therapeutic concept, such as the use of HDACIs in APL, in animal models, it would be desirable that this model system ful®l two important criteria: (i) it should faithfully recapitulate the pathological features of the human disease; and (ii) it should be ideally caused by the same molecular lesion(s) that is thought to cause the human neoplasia. As above mentioned, modeling the disease in the mouse would also be extremely important in assessing in vivo the relevance of a speci®c event in cancer pathogenesis (Figure 2 ). It would be in fact irrational to target the transcriptional activity of PML-RARa for eective APL therapy, if it would become apparent that in APL the oncogenic molecule is not PML-RARa, but, instead, the RARa-PML fusion protein.
Several groups including our own have generated transgenic mice in which X-RARa and RARa-X fusion genes have been expressed in the myeloid/promyocytic compartment (for a review see He et al., 1999) . This analysis has led to three important conclusions: (i) XRARa proteins are critical, albeit not sucient, in causing leukemia since these various transgenic mice develop leukemia, but only after a long pre-leukemic phase; (ii) X-RARa proteins are biologically distinct RARa mutants and directly mediate dierential response to RA. As in human APL, PLZF-RARa transgenic mice develop RA-resistant leukemia, while PML-RARa transgenic mice develop APL-like leukemias which respond to RA. Furthermore, the comparative analysis of the phenotypes in PML-RARa and PLZF-RARa transgenic mice demonstrated that XRARa molecules do not represent identical RARa mutants since both hemopoiesis and leukemogenesis in these mice are biologically distinct (see below and He et al., 1998a) . These ®ndings are in complete agreement with the biochemical/transcriptional ®ndings, thus reinforcing the notion that the targeting of the aberrant transcriptional activity of the various X-RARa molecules could be a critical therapeutic event; and (iii) RARa-X proteins are not sucient for, but do play a crucial role in leukemogenesis. We have shown that PML-RARa transgenic mice develop leukemia with APL features, while PLZF-RARa transgenic mice develop myeloid leukemias that completely lack the distinctive dierentiation block at the promyelocytic stage which characterize human APL, resembling human Chronic Myleogenous Leukemias (CML). We have recently recreated in vivo the dual complexity of human APL by generating transgenic mice, that coexpress RARa-PLZF and PLZF-RARa protein in their myeloid-promyelocytic cellular compartment . We demonstrate in this mouse model that two concomitant genetics events are required to recreate the disease in its uniqueness: while one of the two events is oncogenic, neither event by itself can cause a disease which can be recognized as APL. RARa-PLZF transgenic mice do not develop overt leukemia, nor do they display a block in myeloid dierentiation, but instead show a marked hyperplasia of the myeloid compartment. Strikingly, however, PLZF-RARa/ RARa-PLZF double transgenic mice develop leukemia with classical APL features. Furthermore, RARa-PLZF renders the leukemic blasts further unresponsive to the dierentiating activity of RA.
These faithful RA-sensitive and RA-resistant mouse models of APL will be invaluable to test the ecacy of transcriptionally active compounds in preclinical studies. We are currently challenging in vivo leukemias from PLZF-RARa/RARa-PLZF double transgenic mice and PML-RARa with various HDACIs with or without RA in order to assess if remissions and/or long lasting disease remissions can be induced. These APL models will also be useful to identify and genetically validate target genes deregulated by the various XRARa and/or RARa-X fusion proteins. These genes are themselves potential targets for transcription therapy with molecules that will allow regulating gene expression at the single gene level, such as, for instance, polyamides (see next paragraphs).
Epigenetic control of transcription in cancer pathogenesis and therapy
In APL, pharmacological doses of RA are known to induce the proteolytic degradation of the PML-RARa fusion protein (reviewed in He et al., 1999; Melnick and Licht, 1999) . This mechanism of action combined with the ability of RA to induce the dissociation of the PML-RARa-Corepressor/HDAC complex provides a strong explanation for the clinical ecacy of this compound in APL. As aforementioned, we have generated transgenic mice that recapitulate the response to RA observed in human APL (He et al., 1998a) : as in human APL, PLZF-RARa mice develop RA-resistant leukemia, while PML-RARa develop APL-like leukemias which respond to RA. However, in these RA-resistant leukemia models RA is extremely eective, both in vivo and in vitro, in inducing the disappearance of PLZF-RARa, even at doses which can only cause the partial degradation of PML-RARa . Eective degradation of PLZFRARa by RA has also been reported in vitro in cells from one t(11;17) human APL patient (Koken et al., 1999) . The absence of the PLZF-RARa oncoprotein in treated leukemic cells originates a paradox: how can PLZF-RARa dictate unresponsiveness to treatment, and, in its absence, these eects still be maintained? Although several explanations can be entertained, it is possible that PLZF-RARa might aect transcription through epigenetic mechanisms. Aberrant transcriptional regulation would be therefore maintained throughout cell replication even in the absence of the PLZF-RARa oncoprotein (Figure 4 ). This is supported by the fact that PLZF-RARa through the PLZF moiety can directly interact with nuclear co-repressors and HDACs, thus leading to chromatin remodeling. In this regard, it is also important to notice that gene methylation and histone deacetylation are linked mechanisms of transcriptional repression. A direct connection between gene methylation and histone deacetylation has now been established via proteins such as MeCP2, which binds the mSin-3/HDAC complex to methylated cytosines (Nan et al., 1998) . Thus, aberrant reorganization of chromatin and/or gene methylation might be propagated through cell division in the promyelocytic blasts. Furthermore, methylation, particularly of cytosine residues in the promoter regions of DNA, has long been associated with transcriptional inactivation and cancer pathogenesis (Baylin et al., 1998) .
Two observations are therefore relevant for transcription therapy for cancer: (i) HDAC and methylase activities are critically involved in oncogenesis; and (ii) these activities oer potential targets of anticancer therapy. Indeed, there are several current clinical and preclinical studies to evaluate the potential anticancer eects of agents that are known to either inhibit HDACs (SPB, SAHA, depsipeptide) or demethylate DNA (azacytidine or decitabine) either given alone or in combination (see also following paragraphs). The data obtained in our mouse models will be invaluable to direct these studies and to prioritize or optimize the design of novel clinical trials.
Additional direct applications for transcription therapy with HDAC inhibitors
HDAC-dependent aberrant transcriptional repression has been implicated as a main pathogenic mechanism in forms of cancer other than APL. Straightforward examples to this end are other subtypes of myeloid leukemia and Non-Hodgkin's lymphoma. In particular Diuse Large Cells Lymphomas (DLCL), and Follicular Lymphomas (FL) associated with structural alterations disrupting the BCL6 gene might represent ideal candidates for`transcription therapy' (Magrath, 1990; Lo Coco et al., 1994) . BCL6, as PLZF, is a transcriptional repressor that can repress transcription through recruitment of nuclear receptor co-repressors and HDAC (Dhordain et al., 1997) . The position of the breakpoints within the BCL6 locus have been mapped: as a result, the coding region of BCL6 is left intact, whereas the 5' regulatory region of the gene that contains the promoter sequences is truncated or completely removed. Analysis of the resulting cDNA predicts that the functional consequence of the translocation is the expression of a normal BCL6 protein under the control of a heterologous promoter leading to the loss of its normal pattern of regulation. This model is valid for various translocations involving the BCL6 locus (Ye et al., 1995) . As a result, BCL6 is inappropriately overexpressed within the lymphoid compartment resulting in aberrant transcriptional repression and lymphoid oncogenic transformation. This form of tumor might therefore bene®t of treatment with HDACIs. An additional straightfor- Figure 4 Epigenetic control in leukemogenesis. In APL patients harboring PLZF-RARa both RA and As 2 O 3 treatments can induce the degradation of the fusion oncoprotein (bottom). However, this doesn't result in an eective clinical response. It is therefore conceivable to hypothesize that PLZF-RARa induces the recruitment on DNA of factors that can maintain the transcriptional repressive status and/or the chromatin in its eterochromatic conformation even in the absence of the oncogenic fusion protein. The identi®cation of such factors will be of paramount importance in order to develop eective therapeutic strategies ward example is represented by the M2 subtype of acute myeloid leukemia [according to the FrenchAmerican-British (FAB)], associated with the t(8;21) chromosomal translocation involving the AML1 and ETO genes. The AML1-ETO fusion protein is a potent dominant transcriptional repressor unlike AML1 which can act as a transcriptional activator Gelmetti et al., 1998 and references therein) . Once again the repressive ability of AML1-ETO is due to its ability to interact through the ETO moiety with nuclear co-repressors and HDAC as for the X-RARa proteins of APL Gelmetti et al., 1998) . Preclinical studies with HDACIs in cell lines and xenograf mouse models of DLCL and FL and in mouse models of AML1-ETO-induced myeloid malignancies are presently on going.
HDAC inhibitors as broad anticancer agents
Several classes of HDACIs have been identi®ed including short chain fatty acids (e.g., butyrates) and organic hydroxamic acids [e.g., TSA and hybrid polar compounds (HPCs)] . These compounds were thought to globally aect the repressive activities of transcription factors that utilize HDAC to remodel chromatin and repress transcription. Thus, it would have seemed logical that their biological eects would be very diverse, depending on the histological cell context. By contrast, and surprisingly, several recent reports indicate that HDACIs such as SPB, TSA and suberanilohydroxamic acid (SAHA), a newly synthesized hybrid polar compound (Richon et al., 1996 Finnin et al., 1999) , invariably exerted growth inhibitory, pro-apoptotic and dierentiating activities in various cancer cells lines irrespective of their histological origins (Marks et al., 2000 and references therein) . As an example, these biological activities were observed in leukemia cell lines such as NB4 (APL cell line), or in HL60 and U937 cell lines which do not harbor the APL fusion genes (He et al., 1998b; Vrana et al., 1999) . Inhibition of proliferation and induction of apoptosis by HDACIs were potentiated by RA. RA-induced dierentiation was also enhanced by these HDACIs, though no dierentiation could be induced by HDACIs themselves. Despite their marked anti-tumoral activity these compounds display negligible toxicity in non-neoplastic cells as well as in mice at doses that were able to induce accumulation of acetylated histones in peripheral blood and bone marrow cells (He et al., 1998b) . As above mentioned, these promising preliminary in vitro results prompted us to initiate in our X-RARa leukemia models preclinical in vivo`transcription therapy' trials with HDACIs or HDACIs/RA combinations.
Since HDACIs work as growth inhibitors and inducers of apoptosis in many tumor cell types, these drugs may be useful in combination with dierentiating agents such as RA, or alone, for the therapy of other leukemias and cancers. Indeed, SAHA has been proven eective in suppressing the growth of prostate cancer cells in vitro and in vivo in a xenograf mouse model as well as the growth of neuroblastoma cells in combination with RA (Coey et al., 2000) . Furthermore, SAHA can act as an eective chemopreventive agent as shown by the fact that the volume and incidence of tumors is markedly reduced when SAHA is added to the diet in the classic N-methylnitrosourea (NMU)-induced rat mammary tumor model .
The molecular mechanisms underlying the broad antitumoral actions of HDACIs have not yet been clari®ed. Based of these ®ndings, however, we proposed a model by which HDACIs speci®cally derepress a subset of genes whose transcriptional activation induces cell-cycle arrest, apoptosis and cellular dierentiation ( Figure 5) (He et al., 1998b) . This prediction is supported by the observation that in fact the number of genes that are modulated by these compounds is ®nite and that some of the genes upregulated upon HDACIs encode proteins that act as potent growth/tumor suppressors such as, for instance, the p21WAF1/CIP1 protein Huang et al., 2000) . If these compounds will be proven to be eective anticancer drugs it will be of paramount importance to characterize and validate the genes which are modulated by these compounds, thus de®ning the critical transcriptional events underlying their biological activities. It is also of interest to notice that HDACIs have been found to induce the expression of costimulatory/adhesion molecules such as CD86 in acute myeloid leukemia (AML) cells, thereby possibly stimulating tumor immunity (Maeda et al., 2000) . Altogether, these ®ndings suggest that HDACIs might be utilized as eective anticancer agents. On these ®ndings, phase I and II clinical trials are presently on going with several HDACIs such as SAHA, pyroxamide and depsipeptide (Byrd et al., 1999) .
Modulating gene expression at the single gene level for cancer therapy polyamides
One means of achieving this goal relies on the use of synthetic transcriptional regulators that can be targeted to pre-determined DNA sequences, including the regulatory elements of genes. Such small molecule regulators are based on a family of distamycin-like minor groove binding polyamides that were developed primarily in the Dervan laboratory (Dervan and Burli, 1999) . These molecules are composed of heterocycles such as pyrrole (Py), imidazole (Im), and 3-hydroxypyrrole (Hp) linked via amide bonds. Polyamides form planar crescent shapes that mimic the curvature of the minor groove and typically bind in an antiparallel manner with a 2 : 1 stoichiometry. DNA recognition relies on`slipped side-by-side' pairing of the heterocycles in the minor groove and all four base step can be recognized (White et al., 1998) . Py paired with Im targets a C×G base pair, the converse arrangement leads to the recognition of G×C, a Py-Py pair binds both an A×T and a T×A base pair, whereas an Hp-Py pair prefers a T×A base pair (White et al., 1998) . Further re®nements have led to a series of molecules containing linkers that expand the length as well as the speci®city of recognition. Coupling two single polyamides to give a`hairpin' enhances the anity of resulting species to nanomolar levels with at least two orders of magnitude discrimination between a cognate site versus a single base pair mismatch (Dervan and Burli, 1999) . Moreover, coupling two hairpins via a¯exible tether leads to the recognition of sequences 11 ± 16 bp in length (Trauger et al., 1998) . Thus, these molecules show DNA binding properties that are comparable to most cellular proteins that participate in DNA transactions.
In principle, by utilizing the pairing rules one can design polyamides that recognize most, if not all, natural sequences. Further work by Dervan and colleagues shows that polyamides are cell-permeable, trac to the nucleus, and show no apparent cytotoxicity at the 10 76 M concentrations at which they manifest their regulatory eects in tissue culture cells (Gottesfeld et al., 1997) . This observation has been recently supported by work from Laemmli, and co-workers reporting that when directly fed to Drosophila larvae, at sub-millimolar concentrations, the polyamides do not adversely aect development unless speci®cally designed to do so (Janssen et al., 2000) . Together these results provide support for the power of these molecules to perturb transcriptional circuits without observable toxicity. Furthermore, they demonstrate that polyamides are able to invade endogenous chromatin-bound DNA and exert their eects by competing with endogenous DNA-bound factors.
Next, while inhibition of gene expression as well as the translation of the transcribed mRNA could be attained by several means (see also following paragraphs), bona ®de transcriptional stimulation of targeted genes had presented a signi®cant challenge. This was addressed by the groups of Ptashne and Dervan by generating novel bi-functional polyamide conjugates that are based on coupling a minimal activating domain to polyamides via a¯exible polyether linker (Figure 6 ) (Mapp et al., 2000) . Recently they have also generated a series of such conjugates with tunable transcriptional potencies and included molecular features to further expand the speci®city of these synthetic activators (AZ Ansari et al., 2001, submitted) . Thus, it will be possible to obtain a diverse panel of functional polyamide conjugates that can activate or repress transcription. Compared to other means of targeting DNA, the simplicity of both the delivery and that of designing the recognition code in polyamides makes them powerful and promising tools in the transcription therapy armamentarium.
In principle, these molecules could be utilized to antagonize globally aberrant oncogenic transcriptional activities (e.g.: tethering an activation domain on a generic Retinoic Acid Responsive Elements (RARE) using a polyamide conjugate may revert X-RARa transcriptional repression in APL) or speci®cally (e.g.: tethering an activation domain on a`gene speci®c RARE' such as the one identi®ed in the p21 gene may also be extremely eective). Furthermore, the possibility of rendering polyamides gene speci®c oers, as a corollary approach, the opportunity of utilizing combinations' of gene speci®c polyamides in distinct phases of the neoplasia (e.g.: in situ neoplasia versus invasive tumor versus metastatic cancer).
Alternatively, it is tempting to speculate that such molecules could be utilized to mimic the transcriptional activity of powerful tumor suppressor proteins such as Figure 5 A model for the antitumoral action of HDAC inhibitors. Microarray analysis in various cancer cell lines is demonstrating that HDACIs speci®cally derepress a set of genes whose transcriptional activation induces cell ± cycle arrest, apoptosis and cellular dierentiation. The identi®cation and characterization of these genes will greatly facilitate the understanding of their mechanisms of action p53 or Rb, thus exerting a broader antitumoral activity in tumors of various histological origins. The latter approach may however be complicated by unexpected toxicity if the delivery of the drug is not restricted to the neoplastic tissue.
Synthetic zinc finger transcription factors
An exciting alternative approach to polyamides is represented by synthetic zinc ®nger protein (ZFP) transcription factors designed to target speci®c DNA sequences. These synthetic ZFPs can be fused to repression or activation domains such as VP16 in order to modulate transcription of speci®c genes. ZFP transcription factors can be designed to bind to DNA sequences in the regulatory regions of speci®c genes which are`accessible' within the endogenous chromosomal locus. This approach has been recently successfully utilized in order to activate the expression of the human erythropoietin gene and of the VEGF-A gene respectively (Zhang et al., 2000; Liu et al., 2001 see also Wole, 2001, this issue) . In principle such molecules can be utilized, as the polyamides, to antagonize aberrant oncogenic transcriptional activities or to mimic the transcriptional activity of tumor suppressor proteins. The pharmacokinetics and bioavailability of such compounds remains to be established. It is also dicult to predict if these peptides will elicit host immune responses that may impair their ecacy when utilized in long-term treatments.
Antisense technology
The antisense concept is to selectively bind short, modi®ed DNA or RNA molecules to messenger RNA in cells and prevent the synthesis of the encoded protein. This approach would therefore target not the transcriptional event itself, but its product(s). As anticancer agents, these molecules can be potentially targeted against a number of genes involved in cell transformation, cell survival, metastasis, and angiogenesis. Some of these compounds have now entered human clinical trials and some appear to be eective such as, for instance, an antisense oligonucleotides (ASO) directed against the Bcl-2 proto-oncogene (Jansen et al., 2000) . This compound led to a median 40% decrease in BCL2 protein in human melanoma samples compared with baseline, concomitantly with increased tumor ± cell apoptosis, which was greatly increased after standard treatment with the chemotherapy (dacarbazine). Other ASO including those targeting protein kinase C-alpha, c-raf, and the R1-alpha subunit of protein kinase A are also been tested in phase II trials (Kushner and Silverman, 2000) . While it is dicult at this stage to predict if any of these molecules will be eective anticancer compounds when administered as single agents, antisense technology could be combined with further levels of transcriptional intervention (e.g. HDACIs; polyamides; synthetic ZFPs; see also following paragraph) in order to potentiate their ecacy in reverting the activity of an oncogenic transcription factor. As an example, one could design a polyamide that would tether on a c-myc DNA binding element a transcriptional repression domain, and next combine this approach with antisense(s) that could target genes that are upregulated as a consequence of myc excessive transcription.
Transcription therapy for cancer in combination with other therapeutic agents
In the 60s APL survival rates at MSKCC were, on average, 1 or 2 weeks from diagnosis depending on the quality of care (B Clarkson personal communication). The introduction of chemotherapy had a dramatic impact in prolonging survival in this fatal disorder, but in the late 80s APL was still regarded an incurable disease in the vast majority of cases. It is only recently, in the last decade, that the introduction of RA in the clinical management of the early phase of the disease, followed by conventional chemotherapy has rendered this disease curable with cure rates approximating 70 to 90% of APL cases (He et al., 1999) . Arsenic (Soignet et al., 1998) and/or humanized monoclonal antibodies reactive with cell surface antigens that speci®cally target and kill myeloid leukemia cells such as HuM195 (Jurcic et al., 2000) , and/or, in the near future, HDACIs will possibly further enhance cure rates in APL. The APL paradigm highlights an obvious concept in cancer therapy, not praised enough however, such as that a combinatorial/ sequential approach for cancer treatment are potentially extremely eective. Thus, transcription therapy armamentarium may implement response to established pre-existing treatments. These approaches could be extremely eective in combination with more Figure 6 Schematic structure of novel bi-functional polyamide conjugates. Bi-functional polyamides are generated by coupling a minimal activating/repressing domain to polyamides via a¯exible polyether linker conventional approaches when tailored to distinct phases of the disease. In this respect, distinct pattern of gene expression associated with distinct phases of the disease (e.g. in situ neoplasm versus invasive tumor; invasive cancer versus metastatic cancer) may be modulated for therapeutic purposes. Once again, animal models will be unique tools to test the ecacy of synthetic activators/repressors in association regimens.
Transcription therapy for non-neoplastic diseases
A number of non-neoplastic disorders both inherited and acquired have been recently characterized where aberrant transcription function is implicated as the main pathogenic event. These disorders are all potential direct applications for transcription therapy. In addition, in several cases it is theoretically possible to reactivate in adulthood the expression of genes which are normally expressed only in speci®c embryonic developmental stages in order to rescue for the functional loss of mutated or deleted genes that are critical in adult life. In beta-hemoglobinopathies one could, for instance, reactivate the expression of fetal hemoglobin (HbF). To this end, the butyrate derivative isobutyramide (IBT) has been shown to increase fetal hemoglobin (HbF) in patients with beta-hemoglobinopathies, and reduces transfusion requirements in some patients with homozygous beta-thalassemia (Reich et al., 2000) . Synthetic activators (polyamides or ZFPs) could be used to render these eects even more pronounced. Synthetic activators could also be used in synergy with preexisting`gene therapy' protocols. In this respect it is worth noting that in most instances genes that are delivered are eventually silenced by packaging into heterochromatin. In this respect, it would be possible to design synthetic activators to bind adjacent unrelated sequences, thus accessing a stretch of DNA within the targeted promoter that may not be covered by chromatin. Once bound, the synthetic activator will recruit the chromatin remodeling machinery and expose adjacent promoter sequences. Synthetic activators would thus reactivate such silenced genes speci®cally. These would then be accessible to the polymerase and the natural enogenous activators. Synthetic activators that are speci®c for the gene therapy vector may therefore render possible to speci®cally reactivate or maintain expressed`foreign genes' without aecting the regulation of the endogenous genes.
Conclusions
Transcription therapy is coming of age. The genetic information and the technological tools are available for a comprehensive analysis of gene expression in any disease, as well as to test the relevance of transcription targets genetically and to develop compounds that can modulate speci®cally or globally gene expression. Aberrant transcription factors in the pathogenesis of cancer and non-neoplastic diseases have also been identi®ed and characterized. These molecules or the genes they regulate are also exciting targets for transcription therapy. Murine models of human diseases will allow the validation, in vivo, under physiological conditions, of these novel therapeutic concepts. Through these applications results will undoubtedly follow of tremendous utility for the eective treatment of both cancer and other human diseases.
